Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.450
-0.100 (-3.92%)
Nov 4, 2024, 4:00 PM EST - Market closed
Moleculin Biotech Employees
Moleculin Biotech had 18 employees as of December 31, 2023. The number of employees decreased by 1 or -5.26% compared to the previous year.
Employees
18
Change (1Y)
-1
Growth (1Y)
-5.26%
Revenue / Employee
n/a
Profits / Employee
-$1,398,167
Market Cap
6.97M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Zhongchao | 142 |
Check-Cap | 85 |
Aptose Biosciences | 36 |
Healthcare Triangle | 31 |
Organovo Holdings | 20 |
TFF Pharmaceuticals | 19 |
Galecto | 13 |
Alzamend Neuro | 7 |
MBRX News
- 16 hours ago - Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin - PRNewsWire
- 18 days ago - Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available - PRNewsWire
- 4 weeks ago - Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 - PRNewsWire
- 4 weeks ago - Moleculin to Present at Two Upcoming Investor Conferences - PRNewsWire
- 6 weeks ago - Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma - PRNewsWire
- 7 weeks ago - Moleculin Participates in Virtual Investor "What this Means" Segment - PRNewsWire
- 2 months ago - Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma - PRNewsWire
- 2 months ago - Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference - PRNewsWire